a woman sitting on a bed with her legs crossed, knees are the focus

Does Weight Loss Ease Knee Arthritis Pain?

Retatrutide beat placebo on knee arthritis pain in two trials, but placebo groups improved substantially too. What the numbers show, and what they cannot.

In two phase 3 trials, weekly retatrutide reduced knee osteoarthritis pain by about 1.6 to 1.8 points more than placebo on a 0 to 10 scale over 68 to 80 weeks, alongside 15 to 19 percentage points more weight loss. The drug is not approved, the outcome is self-reported pain, and the placebo group’s own 2.1-point improvement was larger than the gap between arms.

One headline, two promises: an experimental weight-loss injection that also eased knee arthritis pain. Two new trials of retatrutide did find more pain relief than placebo — but the placebo groups improved too, by more than the gap the drug added, and no test in either trial examined the joint itself.

What this means

Among 445 adults with painful knee osteoarthritis and a body-mass index of at least 27 kg/m² in the TRIUMPH-4 trial, pain fell 3.96 and 3.74 points on the 0-to-10 WOMAC scale after 68 weeks of retatrutide 9 mg or 12 mg weekly, against 2.12 with placebo. The gaps were 1.83 points (95% CI −2.37 to −1.30) and 1.61 (−2.16 to −1.07), so the placebo group’s own improvement was larger than the difference between arms. Weight fell 15.4 and 19.2 percentage points more than with placebo. It is unclear whether weight loss alone is responsible.

What the trials tested

TRIUMPH-4 randomized 445 adults to weekly retatrutide 9 mg, 12 mg or placebo for 68 weeks. TRIUMPH-1-OA randomized 574 to 4, 9 or 12 mg or placebo for 80 weeks. Both enrolled people with painful knee osteoarthritis, a body-mass index of at least 27 kg/m², and no diabetes; the retatrutide abstract gives no baseline age, sex mix, pain score, per-arm sizes or analgesic use.

The week-68 result, and the weight that came with it

On the trials’ hybrid-treatment estimand, pain fell 3.96 points with 9 mg and 3.74 with 12 mg against 2.12 with placebo, differences of 1.83 points (95% CI −2.37 to −1.30) and 1.61 (−2.16 to −1.07). Body weight fell 20.0% and 23.7% against 4.6% with placebo, differences of 15.4 percentage points (95% CI −18.7 to −12.1) and 19.2 (−22.4 to −15.9); P<0.001 for both. On the intention-to-treat estimand the pain gaps shrink to 1.70 (95% CI −2.19 to −1.22) and 1.38 (−1.91 to −0.85), each P<0.001.

The second trial, and semaglutide before it

At week 80 in TRIUMPH-1-OA, on the same estimand, pain fell 3.22, 3.48 and 3.64 points with 4, 9 and 12 mg against 1.87 on placebo; differences were 1.35 (95% CI −1.92 to −0.78), 1.61 (−2.20 to −1.02) and 1.77 (−2.34 to −1.20). STEP 9, the earlier semaglutide knee-osteoarthritis trial (407 adults, 68 weeks), reported a 14.2-point pain advantage on a 0-to-100 WOMAC scale, roughly 1.4 points if rescaled to 0-to-10. The gap is similar, but the trials differ in scale, estimand and entry criteria, and no head-to-head comparison exists.

What the abstract cannot show

Serious adverse events were more common with retatrutide than with placebo in both trials, with gastrointestinal events most common; the abstract gives no counts, so the size of the increase is unknown. The measured outcome was self-reported pain, with no cartilage, joint-space or joint-replacement outcome, so nothing here indicates the drug protects the joint. Retatrutide has no approval for any indication. The full paper was not available to us at press time and we read the abstract alone, so no table, appendix or conflict-of-interest statement was examined; the abstract names Eli Lilly as funder.

Terms explained

  • WOMAC pain score: a questionnaire score for osteoarthritis pain of the knee or hip, given here on a 0-to-10 scale where higher means worse pain.
  • Estimand: the precise effect a trial sets out to estimate, including its rule for handling events such as stopping treatment or apparent treatment failure; a hybrid-treatment estimand combines two such rules.
  • Intention-to-treat: an analysis that keeps every participant in the group they were randomly assigned to, including those who stopped taking the drug.
  • Placebo response: improvement among people given an inactive injection, from expectation, extra attention and the natural fluctuation of symptoms.
  • Phase 3 trial: a large randomized study that tests whether an experimental treatment works and how its safety compares with placebo, usually the last stage before regulators review it.

Sources

  1. Schnitzer TJ, Hunter DJ, Conaghan PG, et al. Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity. N Engl J Med. Published online November 8, 2026. https://doi.org/10.1056/NEJMoa2610676 — PMID 43001755: https://pubmed.ncbi.nlm.nih.gov/43001755/
  2. Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med 2024;391(17):1573-1583. https://doi.org/10.1056/NEJMoa2403664 — PMID 39476339: https://pubmed.ncbi.nlm.nih.gov/39476339/
  3. TRIUMPH-4 trial registry, ClinicalTrials.gov NCT05931367 (enrollment 445; primary outcomes WOMAC pain and percent weight change). https://clinicaltrials.gov/study/NCT05931367
  4. TRIUMPH-1 master protocol, ClinicalTrials.gov NCT05929066 (enrollment 2,335). https://clinicaltrials.gov/study/NCT05929066
  5. News signal: US News, “Experimental Weight-Loss Drug Eased Knee Pain Among Arthritis Sufferers.” https://www.usnews.com/news/health-news/articles/2026-11-10/experimental-weight-loss-drug-eased-knee-pain-among-arthritis-sufferers